Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Multiple Myeloma 38Lymphoma 38Lung Neoplasms 25Ovarian Neoplasms 24Melanoma 23Neoplasm Metastasis 21Hematologic Neoplasms 21Carcinoma, Non-Small-Cell Lung 21Leukemia, Myeloid, Acute 19Fallopian Tube Neoplasms 19Breast Neoplasms 18Prostatic Neoplasms 17Glioma 17Sarcoma 14Carcinoma, Renal Cell 14Colorectal Neoplasms 13Uterine Cervical Neoplasms 12Lymphoma, Non-Hodgkin 12Urinary Bladder Neoplasms 11Small Cell Lung Carcinoma 11Neoplasms 11Leukemia, Lymphocytic, Chronic, B-Cell 11Glioblastoma 11Triple Negative Breast Neoplasms 10Pancreatic Neoplasms 10Medulloblastoma 10Wilms Tumor 9Sarcoma, Ewing 9Rhabdomyosarcoma 9Rhabdoid Tumor 9

Interventions

ruxolitinib 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × NIH × Hypereosinophilic Syndrome × Clear all
NCT00044304 2026-03-16

Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
70 enrolled
Myeloid

Hypereosinophilic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡